Protara Therapeutics, Inc.
Clinical-stage biotech developing cell therapies for cancer and rare diseases.
TARA | NDAQ
Overview
Corporate Details
- ISIN(s):
- US74365U1079
- LEI:
- Country:
- United States of America
- Address:
- 345 PARK AVENUE SOUTH, 10010 NEW YORK
- Website:
- https://protaratx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Protara Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing transformative therapies for cancer and rare diseases. The company's lead investigational candidate is TARA-002, a cell therapy based on the immunopotentiator OK-432. It is being evaluated for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs), having received FDA Rare Pediatric Disease Designation for LMs. Protara is also developing IV Choline Chloride, a phospholipid substrate replacement therapy for patients on parenteral support who are choline deficient, with the potential to become the first FDA-approved IV choline formulation for this population.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Protara Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Protara Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Protara Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
